Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | CASR | P41180 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL235309 | 0.84 | DDB1 (0.41) | DDB1CRBNPTGES | |
| SCHEMBL235418 | 0.77 | ADORA3 (0.43) | DDB1CRBN | |
| SCHEMBL609762 | 0.76 | ASIC3 (0.43) | ASIC3EGFRBACE1 | |
| SCHEMBL234738 | 0.76 | ASIC3 (0.43) | ASIC3EGFRBACE1 | |
| SCHEMBL612705 | 0.76 | FGFR3 (0.37) | ASIC3FGFR3KDR | |
| SCHEMBL236213 | 0.75 | DDB1 (0.40) | DDB1CRBNPTGES | |
| SCHEMBL28022209 | 0.75 | RIPK1 (0.57) | RIPK1 | |
| SCHEMBL612632 | 0.75 | DDB1 (0.43) | DDB1CRBNPTGES | |
| SCHEMBL233923 | 0.74 | DDB1 (0.39) | DDB1CRBNPTGES | |
| SCHEMBL237646 | 0.73 | ADORA3 (0.47) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | PDE6D, STARD3, PDE6C | ASIC3 1849/4885HAO1 3561/4885DDB1 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.